Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Common Equity (2018 - 2025)

BridgeBio Pharma's Common Equity history spans 8 years, with the latest figure at -$2.1 billion for Q4 2025.

  • On a quarterly basis, Common Equity fell 42.41% to -$2.1 billion in Q4 2025 year-over-year; TTM through Dec 2025 was -$2.1 billion, a 42.41% decrease, with the full-year FY2025 number at -$2.1 billion, down 42.41% from a year prior.
  • Common Equity hit -$2.1 billion in Q4 2025 for BridgeBio Pharma, down from -$1.9 billion in the prior quarter.
  • Over the last five years, Common Equity for BBIO hit a ceiling of -$389.4 million in Q1 2021 and a floor of -$2.1 billion in Q4 2025.
  • Historically, Common Equity has averaged -$1.2 billion across 5 years, with a median of -$1.2 billion in 2023.
  • Biggest five-year swings in Common Equity: crashed 915.96% in 2021 and later rose 19.86% in 2024.
  • Tracing BBIO's Common Equity over 5 years: stood at -$867.0 million in 2021, then plummeted by 43.41% to -$1.2 billion in 2022, then fell by 8.02% to -$1.3 billion in 2023, then dropped by 8.54% to -$1.5 billion in 2024, then crashed by 42.41% to -$2.1 billion in 2025.
  • Business Quant data shows Common Equity for BBIO at -$2.1 billion in Q4 2025, -$1.9 billion in Q3 2025, and -$1.8 billion in Q2 2025.